OSM Industry Intel • Spring 2026
The NIH Just Tested 8 Longevity Compounds. All 8 Failed. The Reason Should Change How You Formulate.
The gold-standard longevity screen posted a clean sweep of nulls in 2026, including a compound that passed the same test three years ago. The dose gap between those two results is the most important number in the supplement industry right now.
Let us start with the headline, because it is genuinely bad news and pretending otherwise would be insulting: the NIH’s Interventions Testing Program published its 2026 results, eight compounds were tested, and every single one failed to extend lifespan.
Now let us talk about why that is more interesting than it sounds, and why the smartest brands in this category are going to read these results very differently than the panicked headlines will.
Here is the detail that should stop you. One of the compounds that failed in 2026 is astaxanthin. The same astaxanthin that passed the exact same test in 2023, extending median male lifespan by 12%, replicated across three independent sites, peer-reviewed. Same program. Same mouse strain. Same rigorous protocol. Opposite result.
What changed? The dose. The 2023 study that worked used 4,000 ppm in feed. The 2026 study that failed used 800 ppm. One fifth of the dose. And astaxanthin happens to be one of the most notoriously poorly-absorbed compounds in the entire supplement cabinet: fat-soluble, wildly formulation-dependent, with plasma levels that swing enormously depending on how you deliver it.
That is not a story about longevity science being fake. That is a story about a therapeutic window so narrow that the difference between a peer-reviewed win and a total null is how much of the compound actually made it into the bloodstream. For a contract manufacturer, that is not an academic footnote. That is the whole job.
Here is what the ITP actually found, what 24 years of its data says about which compounds win and which lose, and the uncomfortable formulation lessons brands should take from it.
Why the ITP Is the Only Mouse Study That Matters
First, some context on why these results carry weight when a thousand other “compound X extends lifespan in mice” papers do not.
Most preclinical longevity studies are run at a single site, in a single inbred mouse strain, often by the same lab that developed or champions the compound. That is a recipe for results that look spectacular and replicate maybe a third of the time. The supplement industry has built entire product lines on exactly these studies, usually within 48 hours of the press release.
The Interventions Testing Program, funded by the National Institute on Aging since 2002, was designed specifically to break that cycle. It runs identical experiments simultaneously at three completely independent institutions: the Jackson Laboratory, the University of Michigan, and UT Health San Antonio. The mice are UM-HET3, a four-way genetically heterogeneous cross built to approximate the genetic diversity of an actual human population rather than a genetically identical lab strain. No site knows how the others are doing until the study ends. There is no investigator conflict of interest baked in.
In 24 years, the ITP has tested more than 60 compounds. Fifteen have significantly extended lifespan. That is roughly a 25% hit rate, and it looks worse when you remember these compounds were pre-selected as the best candidates with the most compelling mechanisms and the strongest existing evidence. Three quarters of the best ideas in longevity science fail this screen.
The Pattern in What Passes (This Is the Real Strategic Intel)
Look at the winners list and a pattern jumps out immediately. Rapamycin, an mTOR inhibitor, produced roughly 9 to 14% extension in both sexes and remains the most consistent signal in mammalian longevity. Acarbose, a diabetes drug that blunts post-meal glucose spikes, delivered around 8 to 11% in males. Canagliflozin, an SGLT2 inhibitor, hit about 14% in males. 17-alpha-estradiol produced roughly 19% in males. Glycine, a plain amino acid, managed 4 to 6% in both sexes. Aspirin, captopril, epicatechin, and a handful of others round out the list.
Notice what dominates: metabolic pathway modulation. Glucose regulation, mTOR inhibition, AMPK activation. Notice what is largely absent: antioxidants. The antioxidant hypothesis, which underpins an enormous share of longevity supplement marketing, has performed poorly under the industry’s most rigorous screen. Notice also that most of the effects are male-specific, which is a genuine and not-fully-explained wrinkle in the entire field.
Also worth noting: rapamycin, acarbose, and glycine all worked delivered in plain mouse chow. No fancy delivery system required. That matters for the next section, because it means “delivery” is not a universal excuse for every null result. It is a specific problem for specific compounds.
THE FORMULATOR’S TAKE
Resist the temptation to read every ITP null as a bioavailability problem. That is the comfortable interpretation, and for most of these compounds it is probably wrong. Alpha-ketoglutarate has now failed the ITP in two separate cohorts, at two different starting ages, and there is no reason to think a better delivery system would rescue it. Sometimes the honest answer is that the compound does not extend lifespan. But astaxanthin is a genuinely different case, and understanding why it is different is what separates a formulator from a marketer.
The Astaxanthin Case: When Delivery Genuinely Is the Variable
Astaxanthin is the one where the bioavailability argument holds real water, and it holds it for concrete chemical reasons rather than convenient ones.
Astaxanthin is a carotenoid. It is fat-soluble, it has poor oral absorption, and the plasma concentration you achieve depends heavily on the formulation matrix, the fat content of the meal it arrives with, and the particle characteristics of the delivery system. Two products with identical label claims can produce dramatically different blood levels. This is well-documented and not controversial.
So when the ITP gets a clean, triple-site-replicated positive at 4,000 ppm and a null at 800 ppm, the most parsimonious explanation is that the lower dose simply never reached the plasma concentration that drove the original effect. The ITP’s own analysis acknowledges that the prior evidence for benefit under different conditions remains intact. This is not a compound that has been debunked. It is a compound with a real data point and a large question mark about the concentration required to get there.
And here is the part that should land for anyone manufacturing in this space: if a fivefold dose difference is the line between “works” and “does nothing,” then formulation is not a nice-to-have detail. It is the intervention. A poorly-delivered astaxanthin product is not a weaker version of a good one. It may be a different product entirely, sitting on the wrong side of the therapeutic window.
What the ITP Cannot Tell You
Before treating any of these nulls as a final verdict, the program’s limits deserve an honest airing, because they define exactly where the legitimate supplement opportunity still lives.
The ITP measures lifespan. Full stop. Not muscle mass, not cognitive function, not disease burden, not quality of life. A compound that meaningfully preserves strength and independence into old age but adds zero weeks to maximum lifespan fails the ITP completely. Given that healthspan is what most consumers actually care about, that is an enormous blind spot for our category.
The program also can only test compounds deliverable through mouse chow, which excludes anything injectable, anything requiring refrigeration, and anything that degrades during feed processing. And it cannot evaluate timing-based protocols at all, because mice graze continuously and do not fast the way humans do. Intermittent dosing, time-restricted protocols, cycling strategies: all invisible to this screen, and all central to how humans actually use supplements.
Use the ITP as the best preclinical filter available. Do not mistake it for a clinical verdict. A null in ITP mice does not close the human question, but it absolutely should raise your bar for confidence before you build a brand on a mechanism.
What Brands Should Actually Do With This
The reflexive industry response to a headline like “all 8 failed” is either denial or panic, and both are wrong. The useful response is to treat this as the most expensive market research your category has ever been handed for free. Twenty-four years, sixty-plus compounds, three independent sites, no conflicts of interest. The ITP is telling you which bets are bad, which are unresolved, and where the actual craft lives. Here is how to use it.
Lesson 1: For Poorly-Absorbed Actives, Delivery Is the Product
The astaxanthin dose gap is the single most actionable finding here. If a fivefold difference in delivered dose flips a result from significant to null in a controlled mouse study, imagine the variance across commercial products where nobody is measuring plasma levels at all. For fat-soluble and poorly-absorbed compounds (carotenoids like astaxanthin and lutein, curcumin, CoQ10, quercetin, fat-soluble vitamins), the delivery system is not packaging. It is the difference between a functional product and an expensive placebo. Liposomal and emulsified systems exist precisely to solve this problem, and we broke down the mechanics in our guide to how liposomal supplements work and where they fit in your product line. If your brand is competing on a poorly-absorbed active and your only differentiation is label dose, you are competing on a number that may not survive contact with digestion.
Lesson 2: The Antioxidant Story Is Losing. The Metabolic Story Is Winning.
This is the strategic pivot hiding in the ITP data. The compounds that keep passing are metabolic modulators. The compounds that keep failing are, disproportionately, antioxidants. Yet “powerful antioxidant” remains the default marketing frame for half the longevity aisle. Brands building their next generation of products should be reading that pattern carefully and looking hard at ingredients with metabolic mechanisms: glucose regulation, mitochondrial function, AMPK and mTOR pathway involvement. Glycine is a fascinating example that almost nobody is marketing well, given it passed the ITP in both sexes and costs almost nothing.
Lesson 3: Healthspan Is the Honest Opportunity
The ITP does not measure muscle preservation, cognitive function, or daily quality of life, which means a compound can fail this screen and still be genuinely valuable for the outcomes consumers actually buy. Alpha-ketoglutarate is instructive here: it failed the lifespan test twice, but its human epigenetic-clock data is real and it may well have value for endpoints the ITP never looks at. The honest, durable positioning for most supplement brands is healthspan and function, not lifespan extension. That is also, conveniently, the only claim territory that is legally defensible. Muscle preservation is a strong example, and the whole-body case for it is worth understanding, which we covered in our piece on muscle as an endocrine organ.
Lesson 4: Do Not Build a Brand on One Unreplicated Mouse Study
The ITP exists because single-site mouse studies replicate roughly a third of the time. Any brand whose entire product thesis rests on one exciting paper from one lab is carrying a risk that will eventually get called. The mature approach is to look for mechanism plausibility, human data, replication, and a safety profile before committing a SKU, and to be candid in your education content when the evidence is preliminary. We have tried to model that in our own coverage of emerging ingredients, including the microdose lithium orotate story and the apigenin and cellular NAD+ research, both of which are genuinely interesting and both of which come with real caveats we put in writing.
Lesson 5: Format and Dose Precision Are Competitive Advantages
If the therapeutic window is narrow, then batch-to-batch consistency, dose accuracy, and format integrity stop being manufacturing hygiene and start being product differentiation. This is especially true in formats where uniformity is hard to achieve, which is one of the underappreciated technical challenges in the category. Gummies are the obvious example, and the execution issues are real, which we got into in our breakdown of the four key imperatives for gummy manufacturers in 2026. A brand that can credibly say its delivered dose is consistent and verified has something to talk about that most competitors do not.
Claims and Compliance Reality Check
This story cuts both ways on compliance, and it is worth being blunt. On one hand, it is a reminder that lifespan-extension claims were never defensible to begin with, and the ITP data makes that argument for us: fifteen compounds in twenty-four years cleared the bar in mice, and exactly zero have proven lifespan extension in humans. Any brand marketing a supplement as life-extending is on indefensible ground scientifically and legally. On the other hand, the legitimate lane is wide open: supporting healthy aging, supporting cellular energy metabolism, supporting muscle and cognitive function, providing antioxidant support. Those are structure-function claims you can actually stand behind. Bioavailability claims deserve the same discipline: if you are going to say your delivery system improves absorption, you should have data on your specific formulation, not a citation to somebody else’s. AI-driven monitoring is surfacing unsupported claims faster than ever, which we covered in our analysis of how AI is changing supplement discovery.
The Bottom Line
Eight nulls is a rough headline, but the useful reading is not that longevity science is broken. It is that the therapeutic windows are narrower than our industry has been willing to admit, that the antioxidant marketing story is not surviving rigorous testing while the metabolic story is, and that for poorly-absorbed compounds the delivery system may literally be the difference between a peer-reviewed effect and nothing at all. The brands that come out of this stronger will be the ones that stop selling label doses and start caring about delivered doses, that pivot their science story toward mechanisms that are actually winning, and that build on healthspan claims they can defend. That is a harder business than repackaging the last press release. It is also a much more durable one.
Ready to Build?
Build a longevity line where the delivered dose actually matches the label, with a USDA Organic and GMP-certified manufacturer.
Organic Supplement Manufacturing handles formulation, sourcing, manufacturing, and fulfillment for liposomal tinctures, emulsified systems, capsules, powders, and gummies. Low MOQs, full-service support, and a team that reads the primary literature before the label gets printed.
Start a Conversation →Sources: Lin H. The NIH tested 8 longevity supplements this year. All 8 failed. The Longevity Letter, April 2026. Read the analysis. • NIA Interventions Testing Program: program overview. • 2026 ITP cohort results published in GeroScience, doi:10.1007/s11357-026-02201-2. • 2023 astaxanthin result: GeroScience, PMID 38041783.
Disclaimer: This article is intended for supplement brand and contract manufacturing audiences for informational and educational purposes only. It is not intended as medical advice. The ITP is a preclinical mouse program; no compound has demonstrated lifespan extension in humans. Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.